Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia
Status:
Completed
Trial end date:
2012-10-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate how effective and safe SPD422 (Anagrelide
Hydrochloride) is in Japanese subjects, diagnosed with Essential Thrombocythemia, who's
previously treatment has either not been effective or has caused unacceptable adverse
reactions. The study will aim to show that platelet counts can be safely reduced in treated
patients to below 600 x 10^9/L after a minimum of three months treatment. To demonstrate an
positive effect platelet levels will need to remain below 600 x 10^9/L for at least 4 weeks.